Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Travera Inc
Alliance for Clinical Trials in Oncology
Iovance Biotherapeutics, Inc.
Eastern Cooperative Oncology Group
AstraZeneca
Memorial Sloan Kettering Cancer Center